Published in Lancet on September 21, 2002
Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest (2005) 4.74
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J (2009) 2.63
Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS. Intensive Care Med (2010) 2.09
17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med (2012) 1.95
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2014) 1.73
Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest (2007) 1.66
Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD (2012) 1.59
Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest (2008) 1.57
Pulmonary hypertension and the search for the selective pulmonary vasodilator. Lancet (2002) 1.53
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax (2005) 1.29
Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol (2012) 1.26
Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol (2005) 1.24
Severe paediatric pulmonary hypertension: new management strategies. Arch Dis Child (2005) 1.23
Pulmonary arterial hypertension. Orphanet J Rare Dis (2013) 1.18
Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. Crit Care (2010) 1.18
Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest (2013) 1.05
Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. Mol Biol Cell (2009) 1.02
Pulmonary hypertension and chronic cor pulmonale in COPD. Int J Chron Obstruct Pulmon Dis (2007) 1.01
Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag (2006) 0.99
Interfield dysbalances in research input and output benchmarking: visualisation by density equalizing procedures. Int J Health Geogr (2008) 0.98
Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol (2005) 0.98
An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine. Chest (2014) 0.98
Effects and mechanisms of action of sildenafil citrate in human chorionic arteries. Reprod Biol Endocrinol (2009) 0.93
Pathophysiology of pulmonary hypertension in acute lung injury. Am J Physiol Lung Cell Mol Physiol (2012) 0.92
Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest (2007) 0.92
Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol (2007) 0.91
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy. Treat Respir Med (2006) 0.90
Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol (2008) 0.89
Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol (2008) 0.88
Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium. PLoS One (2011) 0.88
Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. Cardiovasc Ultrasound (2005) 0.88
Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. Drug Des Devel Ther (2010) 0.86
Drug treatment of pulmonary hypertension in children. Paediatr Drugs (2014) 0.86
Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respir Res (2005) 0.86
Pulmonary Hypertension and Right Heart Failure in Chronic Kidney Disease: New Challenge for 21st-Century Cardionephrologists. Cardiorenal Med (2013) 0.85
Current challenges in pediatric pulmonary hypertension. Semin Respir Crit Care Med (2013) 0.85
Treatment of pulmonary hypertension. BMJ (2003) 0.85
Four cases with group 3 out-of-proportion pulmonary hypertension with a favorable response to vasodilators. Respir Med Case Rep (2013) 0.85
Noninvasive assessment of acute cardiopulmonary effects of an oral single dose of sildenafil in patients with idiopathic pulmonary hypertension. Heart Vessels (2010) 0.83
Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction. Proc Natl Acad Sci U S A (2013) 0.83
Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme. Cell Signal (2009) 0.83
Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex Heart Inst J (2005) 0.83
Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. Hypertension (2012) 0.83
Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung (2009) 0.82
Right ventricular dysfunction in chronic lung disease. Cardiol Clin (2012) 0.82
Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Drug Des Devel Ther (2014) 0.81
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Ann Med (2015) 0.81
The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases. Biomed Res Int (2014) 0.81
B-type natriuretic Peptide and the right heart. Heart Fail Rev (2004) 0.81
Effects of epoprostenol and sildenafil on right ventricular function in hypoxic volunteers: a tissue Doppler imaging study. Eur J Appl Physiol (2011) 0.79
Platelets in pulmonary hypertension: a causative role or a simple association? Iran J Pediatr (2012) 0.79
Pulmonary heart disease: The heart-lung interaction and its impact on patient phenotypes. Pulm Circ (2013) 0.78
What role does the right side of the heart play in circulation? Crit Care (2006) 0.78
The diagnosis and treatment of idiopathic pulmonary fibrosis. Dtsch Arztebl Int (2013) 0.78
Therapeutic strategies in pulmonary hypertension. Front Pharmacol (2011) 0.78
Pulmonary hypertension in parenchymal lung disease. Pulm Med (2012) 0.77
Lung transplantation for pulmonary hypertension. Pulm Circ (2011) 0.77
Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease. Korean J Intern Med (2007) 0.76
Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. Rheumatol Int (2005) 0.76
Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. Pulm Circ (2015) 0.76
Pulmonary Hypertension Due to Common Respiratory Conditions: Classification, Evaluation and Management Strategies. J Clin Med (2016) 0.76
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Glob Cardiol Sci Pract (2014) 0.76
Pulmonary hypertension caused by sarcoidosis. Clin Chest Med (2008) 0.76
Effect of preoperative oral sildenafil on severe pulmonary artery hypertension in patients undergoing mitral valve replacement. Indian J Pharmacol (2014) 0.76
[Diagnosis and therapy of chronic pulmonary hypertension]. Clin Res Cardiol (2007) 0.75
Effects of extrathoracic mechanical ventilation on pulmonary hypertension secondary to lung disease. J Anesth (2016) 0.75
Propylthiouracil Attenuates Experimental Pulmonary Hypertension via Suppression of Pen-2, a Key Component of Gamma-Secretase. PLoS One (2015) 0.75
Severe Pulmonary Arteriopathy Is Associated with Persistent Hypoxemia after Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension. PLoS One (2016) 0.75
Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives. Can Respir J (2017) 0.75
Stepwise Approach Using Combined Management in Patients with Congenital Heart Disease and Borderline Pulmonary Vascular Disease. Korean Circ J (2015) 0.75
Hypoxic Pulmonary Vasoconstriction in Humans: Tale or Myth. Open Cardiovasc Med J (2017) 0.75
Sildenafil for lung fibrosis and pulmonary hypertension. Lancet (2003) 0.75
The effects of pulmonary vasodilating agents on right ventricular parameters in severe group 3 pulmonary hypertension: a pilot study. Pulm Circ (2016) 0.75
Penile involvement in Systemic Sclerosis: New Diagnostic and Therapeutic Aspects. Int J Rheumatol (2010) 0.75
Acute haemodynamic response in relation to plasma vardenafil concentrations in patients with pulmonary hypertension. Br J Clin Pharmacol (2012) 0.75
Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Future Cardiol (2013) 0.75
High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. Eur J Clin Pharmacol (2012) 0.75
Is sildenafil effective in secondary pulmonary hypertension due to systemic lupus erythematosus? A case report. Clin Rheumatol (2005) 0.75
Sildenafil does not improve steady state cardiovascular hemodynamics, peak power, or 15-km time trial cycling performance at simulated moderate or high altitudes in men and women. Eur J Appl Physiol (2011) 0.75
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Clinical classification of pulmonary hypertension. J Am Coll Cardiol (2004) 5.87
Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med (2013) 5.60
Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 5.31
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest (2005) 4.74
Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res (2012) 4.19
Inhaled iloprost for severe pulmonary hypertension. N Engl J Med (2002) 3.90
Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol (2009) 3.75
Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 3.69
Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 3.63
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J (2004) 3.51
WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest (2009) 3.33
Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res (2007) 3.28
Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem (2003) 3.23
Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med (2004) 3.14
Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One (2008) 2.94
Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2008) 2.90
Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med (2003) 2.90
Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med (2004) 2.80
Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol (2010) 2.72
Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med (2005) 2.69
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation (2006) 2.67
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov (2006) 2.64
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med (2003) 2.59
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol (2010) 2.55
Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell (2011) 2.51
NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. J Clin Invest (2013) 2.48
Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol (2011) 2.39
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat (2006) 2.30
Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med (2008) 2.30
Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol (2006) 2.29
Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation (2002) 2.20
A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation (2009) 2.17
Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J (2012) 2.16
Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med (2014) 2.16
The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice. Am J Respir Crit Care Med (2002) 2.15
Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med (2014) 2.14
Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med (2002) 2.08
L-type calcium channel inhibitor diltiazem prevents aneurysm formation by blood pressure-independent anti-inflammatory effects. Hypertension (2013) 2.05
Monocytes are potent facilitators of alveolar neutrophil emigration during lung inflammation: role of the CCL2-CCR2 axis. J Immunol (2003) 1.95
Thrombin impairs alveolar fluid clearance by promoting endocytosis of Na+,K+-ATPase. Am J Respir Cell Mol Biol (2005) 1.91
Pulmonary vascular disease in the developing world. Circulation (2008) 1.90
Alveolar epithelial cells direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion molecules. J Immunol (2006) 1.89
Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc Natl Acad Sci U S A (2006) 1.89
Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2005) 1.82
MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res (2013) 1.80
Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol (2009) 1.78
Macrophage-expressed IFN-β contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. PLoS Pathog (2013) 1.74
Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med (2002) 1.72
Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med (2002) 1.72
Hyperoxia modulates TGF-beta/BMP signaling in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol (2006) 1.71
Resident alveolar macrophages are replaced by recruited monocytes in response to endotoxin-induced lung inflammation. Am J Respir Cell Mol Biol (2006) 1.70
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med (2010) 1.69
Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. Am J Physiol Heart Circ Physiol (2002) 1.67
Oleic acid inhibits alveolar fluid reabsorption: a role in acute respiratory distress syndrome? Am J Respir Crit Care Med (2004) 1.66
Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol (2005) 1.66
End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 1.63
Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension. Circulation (2013) 1.62
Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. Blood (2010) 1.62
Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest (2013) 1.58
AMP-activated protein kinase regulates CO2-induced alveolar epithelial dysfunction in rats and human cells by promoting Na,K-ATPase endocytosis. J Clin Invest (2008) 1.58
Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med (2009) 1.58